Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-65.0,  Asthma Ages 12-65 2. Ability to provide informed consent 3. Ability to perform pulmonary function tests 4. Female subjects of childbearing potential must have a negative urine pregnancy test upon study entry . 5. Female subjects with reproductive potential must agree to use FDA approved methods of birth control for the duration of the study. 6. Clinically stable asthma at time of entry 7. Participant reported Physician or Licensed Medical Practitioner Diagnosis of Asthma 8. Treatment with medium to high dose ICS (400 mcg to maximum of 2000 mcq per day of fluticasone propionate or equivalent for at least 3 months with a stable dose ≥1 month prior to screening OR a biologic medication for asthma 9. History of asthma exacerbation in the past year, . An exacerbation is defined as: 1) a wheezing episode requiring treatment with systemic corticosteroid (oral, intravenous, or intramuscular) prescribed by a licensed medical providerand/or a biologic medication for asthma 2)An increase in >50% of baseline corticosteroid dose for ≥3 days 3.)An unscheduled visit for acute asthma/wheezing care (licensed medical practitioner/nurse office, urgent care intervention, emergency department, or hospitalization)  Chronic lung disease other than asthma, which may impair lung function. 2. Current smoker or cessation of smoking within 6 months prior to Visit 1. 3. Comorbid disease that might interfere with the evaluation of the Investigational Product (Dupilumab). 4. Pregnancy 5. Other chronic pulmonary disorders associated with asthma-like symptoms, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion), severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways 6. History of premature birth (before 34 weeks gestation) 7. The presence of clinically important co-morbidities. These uncontrolled diabetes, uncontrolled coronary artery disease, acute or chronic renal failure, and uncontrolled hypertension, hepatic or renal insufficiency, gastrointestinal disease, arrhythmia, malignancy, diverticulitis, immunodeficiency (including HIV), opportunistic infection, hepatitis, or any other condition or abnormality that in the opinion of the Principal Investigator would compromise the safety of the patient or quality of data 8. Evidence that the participant or family may be unreliable or poorly adherent to their asthma treatment or study procedures 9. Administration of a live vaccine within 6 weeks of screening. 10. Planning to relocate from the clinical center area before study completion 11. Any other that place the subject at unnecessary risk according to the judgment of the Principal Investigator and/or attending physician(s) of record. 12. Currently participating in an investigational drug trial 13. Being treated with immunosuppressive/immunodulatory or other investigational agents or biologics within 30 days or 5 half-lives of enrollment, whichever is longer 14. History of recent respiratory illness including asthma exacerbations in the past 4 weeks at screening requiring antibiotics or systemic corticosteroids. 15. History of alcohol or illicit substance abuse within 6 months of screening 16. Neutropenia (<1,000/mm3) or thrombocytopenia (<100,000/mm3) or hemoglobin < 100 g/L (10 g/dL) at screening 17. Subjects will be excluded if they have any serious medical problems and cannot perform study procedures. 1. Chronic lung disease other than asthma, which may impair lung function. 2. Current smoker or cessation of smoking < 6 months prior to Visit 1. 4. Pregnant or breast feeding 5. History of premature birth (before 34 weeks gestation) 6. Any other condition or abnormality that in the opinion of the Principal Investigator would compromise the safety of the patient or quality of data 7. Evidence that the participant or family may be unreliable or poorly adherent to their asthma treatment or study procedures 8. Administration of a live vaccine within 6 weeks of screening. 9. Planning to relocate from the clinical center area before study completion 10. Any other that place the subject at unnecessary risk according to the judgment of the Principal Investigator and/or attending physician(s) of record. 11. Currently participating in an investigational drug trial 12. Being treated with immunosuppressive/immunodulatory or other investigational agents or biologics for conditions other than asthma 13. History of recent respiratory illness including asthma exacerbations in the past 4 weeks at screening requiring antibiotics or systemic corticosteroids. 14. History of alcohol or illicit substance abuse within 6 months of screening 15. Neutropenia (<1,000/mm3) or thrombocytopenia (<100,000/mm3) or hemoglobin < 100 g/L (10 g/dL) at screening